Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A positive message from a prospective hospital-based longitudinal study for future considerations

Datta, Bornali; Prakash, Ashish; Yaddanapudi, Kavitha; Ahlawat, Kulbir; Tripathy, Jaya Prasad; Goyal, Pinky; Jaiswal, Anand; Singh, Rajesh; Pipavath, Sudhakar; Raghu, Ganesh

doi:10.1016/j.rmed.2023.107261

Respiratory Medicine

2023

DOI: 10.1016/j.rmed.2023.107261

|View full text |Cite

Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A positive message from a prospective hospital-based longitudinal study for future considerations

Bornali Datta

Ashish Prakash

Kavitha Yaddanapudi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cardiopulmonary Complications after Pulmonary Embolism in COVID-19

Suarez-Castillejo,

Calvo,

Preda

et al. 2024

IJMS

View full text Add to dashboard Cite

Although pulmonary embolism (PE) is a frequent complication in COVID-19, its consequences remain unknown. We performed pulmonary function tests, echocardiography and computed tomography pulmonary angiography and identified blood biomarkers in a cohort of consecutive hospitalized COVID-19 patients with pneumonia to describe and compare medium-term outcomes according to the presence of PE, as well as to explore their potential predictors. A total of 141 patients (56 with PE) were followed up during a median of 6 months. Post-COVID-19 radiological lung abnormalities (PCRLA) and impaired diffusing capacity for carbon monoxide (DLCOc) were found in 55.2% and 67.6% cases, respectively. A total of 7.3% had PE, and 6.7% presented an intermediate–high probability of pulmonary hypertension. No significant difference was found between PE and non-PE patients. Univariate analysis showed that age > 65, some clinical severity factors, surfactant protein-D, baseline C-reactive protein, and both peak red cell distribution width and Interleukin (IL)-10 were associated with DLCOc < 80%. A score for PCRLA prediction including age > 65, minimum lymphocyte count, and IL-1β concentration on admission was constructed with excellent overall performance. In conclusion, reduced DLCOc and PCRLA were common in COVID-19 patients after hospital discharge, but PE did not increase the risk. A PCRLA predictive score was developed, which needs further validation.

show abstract

Cardiopulmonary Complications after Pulmonary Embolism in COVID-19

Suarez-Castillejo,

Calvo,

Preda

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A positive message from a prospective hospital-based longitudinal study for future considerations

Cited by 1 publication

References 10 publications

Cardiopulmonary Complications after Pulmonary Embolism in COVID-19

Cardiopulmonary Complications after Pulmonary Embolism in COVID-19

Contact Info

Product

Resources

About